Alto Neuroscience Receives FDA Fast Track Designation for Drug Candidate ALTO-101 for Cognitive Impairment in Schizophrenia
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best young stocks with huge upside potential.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Falcon Edge Capital Richard Gerson And Navroz D. Udwadia | 3,707,757 | $65,998,075 | 8.09% | |
| 2. | Vestal Point Capital Ryan Wilder | 2,485,000 | $44,233,000 | +162% | 1.5% |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,823,196 | $32,452,889 | 2.16% | |
| 4. | Perceptive Advisors Joseph Edelman | 1,784,393 | $31,762,195 | +1049% | 0.57% |
| 5. | Point72 Asset Management Steve Cohen | 1,606,954 | $28,603,781 | +21% | 0.03% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.22 | 2,931 | $38,747.82 | 39,851 | 2024-07-10 | Filing | |
| $13.15 | 1,388 | $18,252.20 | 36,920 | 2024-07-09 | Filing | |
| $12.53 | 10,681 | $133,832.93 | 35,532 | 2024-07-09 | Filing | |
| $16.56 | 4,550 | $75,348.00 | 26,866 | 2024-03-28 | Filing | |
| $15.80 | 1,600 | $25,280.00 | 22,316 | 2024-03-28 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,365,847 | $24,312,077 | 0% | |
| 2. | 1,119,578 | $19,928,488 | 0% | |
| 3. | 607,874 | $10,820,158 | 0% | |
| 4. | 474,373 | $8,443,839 | 0% | |
| 5. | 379,000 | $6,746,200 | 0% |